Serum procalcitonin level may reflect non-infectious inflammation.
INTRODUCTION
Procalcitonin, a prohormone of 116 amino acids is the precursor for the calcium homoeostasis hormone, calcitonin, which is found in the thyroid C cells and the pulmonary endocrine cells. 1 It has been found to circulate at very low concentrations in normal serum and is presumably produced by the neuroendocrine cells in the thyroid gland and in the lungs. 1 Procalcitonin plays a major role in systemic inflammation and induces a dose-dependent increase in TNFa secretion. 2 In a study on blood of normal human volunteers, recombinant human procalcitonin had an inhibitory effect on leucocyte migration with marked malfunction of neutrophils that is known to occur during sepsis. 2 Data from experimental models demonstrated that human recombinant procalcitonin induced a dose-dependent increase in leucocyte-derived tumour necrosis factor alpha (TNFa) secretion from isolated lymphocytes. 2 Current lines of evidence indicate that mediators such as TNFa, as well as interleukin (IL)-1b and IL-6, comprise the specific proximate stimuli to hyperprocalcitonaemia. 3, 4 TNFa is a potent stimulant of procalcitonin production and may further reinforce the procalcitonin levels in a self-perpetuating cascade fashion. 3, 4 Multiple studies have demonstrated that serum levels of procalcitonin are markedly increased in humans with severe infection. 5 Procalcitonin has also been evaluated in chronic inflammatory and autoimmune conditions as a marker of disease activity. [6] [7] [8] Interestingly, in patients with Wegener's granulomatosis, serum procalcitonin level (SPL) was markedly elevated in patients with highly active disease in comparison with those with inactive disease. 6 In children with active autoimmune processes, slight elevation of procalcitonin concentration was observed without any evidence of bacterial infection. 7 In patients with inflammatory bowel diseases (IBD), the association of procalcitonin with disease activity remains poorly investigated. Two studies in IBD patients demonstrated that procalcitonin had good diagnostic value for differentiating flares of IBD from self-limited colitis, but found conflicting results when evaluating procalcitonin as a biological marker of disease activity. 9, 10 Only one study evaluated the diagnostic value of SPL in determining disease activity in IBD, but included a relatively small number of patients with Crohn's disease (CD), which prevents drawing conclusions. 11 Furthermore, none of the aforementioned studies evaluated the correlation of procalcitonin with endoscopic and radiological markers of IBD activity. [9] [10] [11] Finally, the additional diagnostic benefit of SPL to that of C-reactive protein (CRP) has never been evaluated in IBD.
The aims of this study was therefore to assess for the first time the correlation of SPL with clinical, biological, endoscopic and radiological markers of disease activity in patients with IBD and to evaluate the additional diagnostic benefit of measuring SPL to that of CRP in the assessment of disease activity in IBD.
MATERIALS AND METHODS

Study design
We performed an observational study of a single-centre cohort. Data were retrieved from a prospectively maintained database.
Population studied
All consecutive patients seen between 15 January 2008 and 1 June 2010 who had concomitant clinical, biological and radiological evaluation with or without concomitant colonoscopy during an IBD flare or to rule out active disease were included in the study. All investigations were prescribed at the discretion of the physician. Patients were included in the analysis if an intercurrent infection was ruled out by stool analysis for enteric pathogens and Clostridium difficile toxin, and quantitative real-time polymerase chain reaction in colonic biopsies for the detection of active cytomegalovirus infection in patients with severe or steroid-refractory colitis. Our cohort of IBD patients is reported to The Commission Nationale de l'Informatique et des Libertés (N°1404720), which supervises the implementation of the 6 January 1978 Act on data processing, data files, and individual liberties as amended by the 6 August 2004 Act relating to protection of individuals with regard to the processing of personal data.
Clinical and biological markers of disease activity Clinical disease activity was calculated using data collected on the day of patient's morphological evaluation: the simple clinical colitis activity index (SCCAI) 12 
Endoscopy
All colonic lesions were rated according to standardized scoring systems for UC and CD as routinely used in the department. In patients with UC, the severity and extent of endoscopic lesions were assessed by the Modified Baron score. 15 Five endoscopic segments were defined such as rectum, sigmoid, left colon, transverse colon and right colon. The Modified Baron score was applied to each segment to obtain a segmental Modified Baron score. A total score was calculated from the sum of the segmental scores to obtain the total Modified Baron score. In patients with CD, the severity of endoscopic lesions was assessed by the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD). 16 Colonoscopy was considered concomitant to MR-DWI-colonography if it was performed within 48 h after the radiological examination, without any therapeutic intervention during this interval.
Magnetic resonance colonography
The morphological evaluation of IBD patients consisted of a magnetic resonance diffusion-weighted imaging colonography (MR-DWI-colonography) without oral or rectal preparation and with or without concomitant colonoscopy as described previously. 17 Radiological evaluation of disease activity was performed using the six-items Magnetic resonance score (MR-score). 17 The MR-score includes six radiological signs: (i) DWI hyperintensity, (ii) rapid gadolinium enhancement after intravenous contrast medium administration, (iii) differentiation between the mucosa-submucosa complex and the muscularis propria, (iv) bowel wall thickening, (v) parietal oedema and (vi) the presence of ulcer(s). The definition of each radiological sign of the MR-score is provided as supplementary material (Supplemental Table S1 online). The presence and absence of a radiological sign in a given segment were rated '1' and '0' respectively. The segmental MR-score (MR-score-S) was calculated as the sum of the numerical values obtained for the six radiological signs for a given segment. The total MR-score (MR-score-T) was calculated as the sum of the MR-score-S in a patient, with values ranging from 0 to 30 in the case of UC and from 0 to 36 in the case of CD. P Pr ro oc ca al lc ci it to on ni in n i in n i in nfl fla am mm ma at to or ry y b bo ow we el l d di is se ea as se es s Aliment Pharmacol Ther 2010; 32: 1135-1144
Definition of active disease and severe disease To achieve a pooled analysis, IBD patients were considered to have an active disease if they had a CDAI ‡150 in case of CD and in case of UC if they had 'mild', 'moderate' or 'severe' UC according to Truelove and Witts severity index, 13 and a SCCAI >5. 18 Patients were considered to have severe disease if they had a CDAI ‡300 or a 'severe' UC according to Truelove and Witts severity index. 13 Statistical analyses Quantitative variables are described as means and standard deviation (s.d.), or as medians and percentiles (I.Q.R. for Inter Quartile Range: 25-75th) in the case of an abnormal distribution. Proportions are expressed as percentages and 95% confidence intervals. All correlations were studied using Spearman's nonparametric correlation Clinical evaluation of disease activity.
à Endoscopic evaluation of disease activity. § Radiological evaluation of disease activity. coefficients. The diagnostic accuracy of serum procalcitonin (lg ⁄ L) for detecting severe forms of IBD was evaluated using receiver operating characteristic (ROC) analysis according to DeLong et al. 19 to calculate the sensitivity, specificity, positive and negative predictive values, and area under the receiver operating characteristic curve (AUROC) with the associated P-value. The comparison of AUROCs was carried out using the procedure proposed by DeLong et al. 19 The comparison of serum procalcitonin values between different groups of disease activity was performed using the Kruskal-Wallis test. All the reported P-values were two-sided, and P-values of <0.05 were considered statistically significant. Statistical analyses were performed using MedCalc software, version 11.3.3.0 (MedCalc Software, Mariakerke, Belgium). P Pr ro oc ca al lc ci it to on ni in n i in n i in nfl fla am mm ma at to or ry y b bo ow we el l d di is se ea as se es Correlation of serum procalcitonin level with biological and radiological markers of disease activity. Serum procalcitonin level was strongly correlated with CRP (r = 0.592, P < 0.001) (Figure 2 ), albumin (r = )0.609, P < 0.001), haemoglobin (r = )0.500, P < 0.001) and MR-score (r = 0.552, P < 0.001), and was significantly correlated with serum iron (r = )0.283; P = 0.03) and platelets (r = 0.393, P = 0.003). SPL was not correlated with leucocytes (r = 0.1, P = 0.5).
RESULTS
Between
In the whole group of IBD patients, SPL was significantly correlated with CRP in patients with active disease (Supplemental Table S2 online). In patients with inactive IBD, SPL and CRP were not significantly correlated; however, this result is not reliable due to the risk of type II error related to the small sample size (n = 13).
Crohn's disease Correlation of serum procalcitonin level with clinical, biological, endoscopic and radiological markers of activity. In patients with CD (n = 30), SPL was strongly correlated with all disease activity markers namely, CDAI (r = 0.545, P = 0.002), CRP (r = 0.626, P = 0.0002) (Figure 2 ), albumin (r = )0.813, P < 0.0001), haemoglobin (r = )0.709, P < 0.0001), SES-CD (r = 0.797, P = 0.0006) and MR-score (r = 0.599, P = 0.0005) ( Table 3) . SPL was significantly correlated with CRP in patients with active CD as opposed to patients in remission (Supporting Information Table S2 ).
Diagnostic accuracy of serum procalcitonin for detecting disease activity. In patients with CD, using ROC analysis, an SPL >0.14 lg ⁄ L demonstrated a high accuracy for detecting severe disease as defined by a CDAI ‡300 with a sensitivity of 100%, a specificity of 96%, positive and negative predictive values of 88% and 100% respectively, and an AUROC of 0.963 [95% Confidence Interval (CI), 0.822-0.999; P = 0.0001] (Table 4 and Figure 3) . In CD patients, SPL >0.14 lg ⁄ L had a sensitivity of 67%, a specificity of 100%, and an AUROC of 0.815 (95% CI, 0.631-0.932; P = 0.0005) for detecting patients with a CRP >30 mg ⁄ L (Table 4) . Consistently, the median SPL was significantly higher in patients with a CDAI ‡300 (0.21 lg ⁄ L; IQR 25-75th, 0.19-0.30) compared with those with a CDAI <300 (0.07 lg ⁄ L; IQR 25-75th, 0.05-0.07) (P = 0.0002).
In comparison with a CRP cut-off of 5 mg ⁄ L, an SPL cut-off of 0.05 lg ⁄ L had the same diagnostic accuracy (AUROC) for detecting active or severe CD (P = 0.90 and P = 0.77 respectively). However, the combination of CRP cut-off of 5 mg ⁄ L with an SPL cut-off of 0.05 lg ⁄ L, called the 'SPL-CRP strategy', yielded a better specificity for diagnosing active or severe CD (Table 5) . Moreover, the diagnostic accuracy of the SPL-CRP strategy was Table 5 and Figure 4 ).
Ulcerative colitis
Correlation of serum procalcitonin level with clinical, biological, endoscopic and radiological markers of activity. In patients with UC (n = 27), SPL was correlated with the SCCAI (r = 0.423, P = 0.03), CRP level (r = 0.548, P = 0.003) and MR-score (r = 0.536, P = 0.004). In contrast, SPL was not correlated with albumin, haemoglobin and the total modified Baron score (Table 3) . SPL was significantly correlated with CRP in patients with active UC as opposed to patients with inactive UC (Supporting Information Table S2 ).
Diagnostic accuracy of serum procalcitonin for detecting disease activity. In patients with UC, ROC analysis did not reveal any significant threshold of SPL for the detection of active or severe disease (P = 0.08 and P = 0.2 respectively) ( Table 6 ). The SPL-CRP strategy did not yield a better accuracy for diagnosing active or severe UC in comparison with CRP alone (Table 5) .
DISCUSSION
This is the first study showing that SPL is correlated with clinical, biological, endoscopic and ⁄ or radiological disease activity in patients with IBD. To date, three studies have evaluated procalcitonin in IBD. [9] [10] [11] By pooling UC and CD patients, we found that SPL was significantly higher in patients with active IBD. These results are consistent with those of a previously reported study. 9 Consistently, by pooling UC and CD patients, SPL was significantly higher in patients with a CRP >5 mg ⁄ L and was correlated with CRP levels. This finding is also consistent with that in the study by Oruc et al. that demonstrated a significant correlation between SPL and CRP in patients with IBD. with the CDAI, while no correlation was found with CRP level. 9 In contrast, in the study by Thia et al., SPL showed no correlation with CD activity using the Harvey-Bradshaw index (HBI). 10 This discrepancy may be partly explained by the fact that CD activity has been scored with the HBI in the study by Thia et al., 10 in contrast to our study and that of Herrlinger et al. 9 that used the CDAI as CD activity score. In the study by Oruc et al., SPL was not correlated with CDAI. 11 However, this study included only nine CD patients, which prevents any conclusion. It is noteworthy that none of the three studies 9-11 had evaluated endoscopic or radiological markers of disease activity. Our study showed that in patients with UC, SPL was correlated with the SCCAI, CRP and the MR-score score, whereas no correlation was found with endoscopic disease activity scores. Among the three studies that evaluated SPL in IBD patients, [9] [10] [11] only one has specifically evaluated the SPL in the subgroup of patients with UC, and did not show any correlation between SPL and clinical disease activity. 10 This difference may be partly explained by the fact that UC activity has been scored with the Physician Global Assessment 20 in the study by Thia et al., 10 in contrast to our study that used the SCCAI, which is a well validated disease activity index for UC. 21, 22 In the study by Oruc et al. a procalcitonin cut-off value of 0.05 lg ⁄ L, found in ROC analysis, had a poor accuracy (sensitivity, 67%; specificity 42%) for detecting active IBD as defined by a CDAI >150, or a 'moderate' or 'severe' UC according to Truelove and Witts severity index. 13 Importantly, by using ROC analysis, we were able to identify an SPL cut-off of 0.14 lg ⁄ L as having a high accuracy (sensitivity, 100%; specificity, 95%) for detecting severe forms of CD as defined by a CDAI ‡300. Interestingly, by adding SPL measurement to routine CRP evaluation (The SPL-CRP strategy), we were able to double the specificity of the SPL-CRP strategy for diagnosing active or severe forms of CD when compared with a 'CRP alone'-based strategy.
Overall, we found that the performance of procalcitonin for evaluating disease activity was weaker in UC compared with CD. Consistently, there was no cut-off value for SPL capable of detecting severe forms of UC in our study. This is consistent with previous reports. 9, 10 From a mechanistic point of view, one can speculate that the best correlation of procalcitonin with the degree of activity of CD is linked to the fact that TNFa plays a central role in the pathogenesis of this disease.
In conclusion, our results indicate that procalcitonin might be useful in clinical practice to assess disease activity in patients with CD. Notably, we demonstrated for the first time that SPL was correlated with endoscopic and radiological markers of activity in CD, and with radiological activity in UC. In patients with CD, a threshold of 0.14 lg ⁄ L for procalcitonin may detect the most severe forms of the disease. The combination of procalcitonin with CRP would be more efficient than CRP alone for the diagnosis of active or severe CD. Our results need to be confirmed in independent studies.
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